Reuters logo
BRIEF-FDA Curcumin Investigation supports Imprimis statement
September 14, 2017 / 12:04 PM / 2 months ago

BRIEF-FDA Curcumin Investigation supports Imprimis statement

Sept 14 (Reuters) - Imprimis Pharmaceuticals Inc

* FDA Curcumin Investigation supports Imprimis statement

* Imprimis Pharmaceuticals Inc - ‍provided an update regarding FDA Medwatch notice issued on August 4, 2017​

* Imprimis Pharmaceuticals-confirms that upon discovery of supplier’s mislabeling, it immediately terminated its business relationship with supplier​

* Imprimis Pharmaceuticals Inc - will continue to review its operating procedures and make changes where appropriate to protect patient safety​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below